Synedgen
Claremont, United States· Est.
Synedgen’s current lead asset is MIIST305, a clinic-ready, orally delivered therapeutic that repairs GI mucosal injury. MIIST305 restores GI function and reduces unchecked inflammation and damage.
Private Company
Total funding raised: $6.8M
About
Synedgen’s current lead asset is MIIST305, a clinic-ready, orally delivered therapeutic that repairs GI mucosal injury. MIIST305 restores GI function and reduces unchecked inflammation and damage.
Infectious DiseaseWound HealingDrug Delivery
Funding History
3Total raised:$6.8M
Series A$5M
Grant$1.5M
Grant$300K